Analysis of PAI‐1 Gene Expression in Vivo Using in Situ Hybridization

D. Loskutoff,M. Sawdey,M. Keeton,J. Schneiderman,I. Lang,R. Schleef

DOI: https://doi.org/10.1111/j.1749-6632.1994.tb12052.x

IF: 6.499

1994-04-01

Annals of the New York Academy of Sciences

Abstract:Historically, most studies to define the fibrinolytic system and understand its complex regulation have employed purified proteins, cultured cells or whole blood itself. Although these approaches have been essential for the development of many of our current concepts of the plasma fibrinolytic system, they have provided little information about the origin of the various fibrinolytic components present in blood, or how their synthesis is altered in various disease states. The complementary DNA (cDNA) for all of the human fibrinolytic proteins and for some of their counterparts in other species has been cloned. These probes are now widely available and can be used to study the expression of fibrinolytic genes in vivo in both normal and diseased tissues. In this regard, we have begun to use the cDNA for type 1 plasminogen activator inhibitor (PAI-1) in Northern blotting and in situ hybridization experiments to define its tissue distribution and regulation. PAI-I i s a rapid and specific inhibitor of both tissue-type and urokinase-type plasminogen activators (t-PA and u-PA, respectively) and appears to be the primary regulator of plasminogen activation in vivo.’.’ Numerous observations suggest that the expression of PAI-I in vivo is precisely regulated and that the inappropriate expression of this potent inhibitor may suppress the normal fibrinolytic system of the tissues and create a local prothrombotic state. If this hypothesis is correct, then this condition may result in pathological fibrin deposition after injury and/or tissue factor expression. The recent demonstration that PAL 1 mRNA levels are elevated in the kidneys of mice with renal d i ~ e a s e , ~ , ~ in atherosclerotic human a r t e r i e ~ . ~ and in the pulmonary arteries of individuals with chronic thromboembolic disease,6 is consistent with this possibility because these conditions are associated with fibrin accumulation. These studies are discussed in this review.